[{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Entera Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Termination","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Entera Health","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Entera Health"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Gaelan Medical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Gaelan Medical","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Gaelan Medical"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Phil","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Omeprazole Magnesium","moa":"||K-ATPase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"RedHill Biopharma \/ Phil","highestDevelopmentStatusID":"15","companyTruncated":"RedHill Biopharma \/ Phil"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GSK"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"GIBF2","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ GIBF2","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ GIBF2"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ Inapplicable"},{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Curetis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Curetis \/ BioVersys AG","highestDevelopmentStatusID":"6","companyTruncated":"Curetis \/ BioVersys AG"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"AMR Action Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioVersys AG \/ AMR Action Fund","highestDevelopmentStatusID":"6","companyTruncated":"BioVersys AG \/ AMR Action Fund"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Rifabutin","moa":"RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioVersys AG \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioVersys AG \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Immunology","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"ISRAEL","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Gastroenterology","graph2":"Phase II","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Financing","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Public Offering","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Clarithromycin","moa":"||50S ribosomal subunit","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RedHill Biopharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Rifabutin Pfizer Brand
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
